Revenue
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Viridian Therapeutics, Inc.\DE (VRDN)
Price$22.78Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.8M | $302,000 | $314,000 | $1.8M | $3.0M | $1.1M | $4.5M | $8.4M | $4.0M | $3.5M | $5.7M | $6.5M | $5.5M |
| Gross profit | — | — | — | — | — | — | — | — | — | $929,000 | $3.2M | $3.1M | $2.7M |
| Gross margin | — | — | — | — | — | — | — | — | — | 26.72% | 56.68% | 48.09% | 49.41% |
| Research & development | $338.9M | $238.3M | $159.8M | $100.9M | $56.9M | $28.3M | $34.8M | $30.4M | $19.6M | $13.7M | $1.0M | $347,000 | $225,000 |
| Operating expenses | $434.2M | $299.3M | $254.8M | $136.1M | $82.7M | $111.4M | $46.4M | $41.5M | $30.5M | $20.5M | $13.7M | $11.2M | $4.5M |
| Operating income | −$363.4M | −$299.0M | −$254.4M | −$134.3M | −$79.7M | −$110.4M | −$42.0M | −$33.1M | −$26.5M | −$17.0M | −$11.2M | −$6.9M | −$197,000 |
| Operating margin | −512.91% | −99,018.21% | −81,035.03% | −7,579.23% | −2,690.79% | −10,512.38% | −941.02% | −394.51% | −662.80% | −488.55% | −196.06% | −105.91% | −3.59% |
| EBITDA | −$362.9M | −$298.5M | −$253.9M | −$134.0M | −$79.6M | −$110.1M | −$41.7M | −$32.8M | −$26.2M | −$16.6M | −$11.0M | −$6.7M | −$49,000 |
| EBITDA margin | −512.27% | −98,839.40% | −80,868.79% | −7,564.84% | −2,686.74% | −10,489.62% | −934.57% | −391.16% | −655.11% | −478.75% | −192.83% | −103.69% | −0.89% |
| Net income | −$342.6M | −$269.9M | −$237.7M | −$129.9M | −$79.4M | −$110.7M | −$41.9M | −$32.7M | −$26.5M | −$17.3M | −$11.3M | −$7.9M | −$2.2M |
| Net profit margin | −483.57% | −89,387.09% | −75,711.46% | −7,329.23% | −2,680.16% | −10,544.29% | −938.65% | −389.97% | −662.30% | −496.81% | −198.53% | −121.68% | −39.34% |
| Basic EPSper basic share | -$3.32 | -$3.07 | -$5.31 | -$4.05 | -$6.66 | -$31.13 | -$20.04 | -$16.50 | -$20.70 | -$423.15 | -$315.30 | -$787.50 | -$2,751.75 |
| Diluted EPSper diluted share | -$3.32 | -$3.07 | -$5.31 | -$4.05 | -$6.66 | -$31.13 | -$20.04 | -$16.50 | -$20.70 | -$423.15 | -$315.30 | -$787.50 | -$2,751.75 |
Owners
Reported shareholders
14.66%of listed shares
FMR LLC16.6M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 14.66%16.6M shares |
BlackRock, Inc. | 7.55%8.55M shares |
Bellevue Group AG | 5.94%6.73M shares |
Paradigm Biocapital Advisors LP | 5.94%6.72M shares |
Kynam Capital Management, LP | 5.70%6.45M shares |
STATE STREET CORP | 5.41%6.12M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 5.08%5.75M shares |
Fairmount Funds Management LLC | 4.50%5.09M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.04%4.58M shares |
Deep Track Capital, LP | 3.17%3.59M shares |
Venrock Adviser, LLC | 2.88%3.26M shares |
WELLINGTON MANAGEMENT GROUP LLP | 2.76%3.13M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 2.43%2.75M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.21%2.5M shares |
Avoro Capital Advisors LLC | 2.21%2.5M shares |
BAKER BROS. ADVISORS LP | 2.10%2.38M shares |
Point72 Asset Management, L.P. | 2.07%2.34M shares |
Caligan Partners LP | 1.94%2.19M shares |
NOVO HOLDINGS A/S | 1.89%2.14M shares |
TANG CAPITAL MANAGEMENT LLC | 1.58%1.79M shares |
Percentages use 113.24M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 11, 2026Form 4 | Fairmount Healthcare Fund II L.P. +2Director,TenPercentOwner | BuyCommon Stock · indirect | 1.18M | $17.00 | $20.00M | 5.09M |
| Dec 31, 2025Form 4 | Tousignant JenniferChief Legal Officer | SellCommon Stock | 2.3K | $31.16 | $70.8K | 0 |
| Oct 23, 2025Form 4 | Fairmount Healthcare Fund II GP LLC +2Director,TenPercentOwner | BuyCommon Stock · indirect | 454.5K | $22.00 | $10.00M | 3.91M |
| Sep 27, 2024Form 4 | Beetham Thomas W.Chief Operating Officer | BuyCommon Stock | 5.0K | $23.41 | $117.0K | 6.0K |
| Sep 27, 2024Form 4 | Mahoney Stephen F.President and CEO | BuyCommon Stock | 21.4K | $23.33 | $499.3K | 21.4K |